

FOI 3652

19th March 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Appendix A

Q1a – How many patients were treated with the following drugs for the following diseases from the start of October 2025 to the end of December 2025?

Please use the latest available 3 months if October to December is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Response:

Current patients as of 10.3.26

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis
Adalimumab	259	151	75	246
Apremilast	0			0
Bimekizumab	17			6
Brodalumab	5			
Certolizumab Pegol	5			31
Deucravacitinib	0			
Etanercept	<5			66
Etrasimod			0	
Filgotinib			0	
Golimumab			<5	27
Guselkumab	67	0	0	14
Infliximab (Biosimilars)	<5	71	66	9
Infliximab (Remicade)	0	0	0	0
Ixekizumab	123			54
Mirikizumab		0	0	
Ozanimod			0	
Risankizumab	134	12	3	<5

Secukinumab	30			93
Tildrakizumab	5			
Tofacitinib			<5	<5
Upadacitinib		26	20	8
Ustekinumab	25	68	38	<5
Vedolizumab		53	63	

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net